

**PRESS RELEASE**

Lund, May 20<sup>th</sup>, 2008

For release 9 a.m. CET, May 20<sup>th</sup>, 2008

**TFS Trial Form Support International acquires all shares of IMRO TRAMARKO Holding B.V.**

On May 19<sup>th</sup> 2008, TFS Trial Form Support International (TFS) has signed an agreement to acquire IMRO TRAMARKO Holding B.V., an independent clinical contract research organization (CRO), based in Berghem, the Netherlands. The acquisition will expand TFS operational reach to the Benelux region and Germany. TFS acquired all shares of the parent company, IMRO TRAMARKO Holding B.V. (IMRO TRAMARKO) and the subsidiaries IMRO TES and IMRO TRAMARKO International. IMRO TRAMARKO is a privately held company owned by Mr. Peter Monster and Mr. Ed Dawson and was established in 1988. The company has successfully for 20 years managed clinical trials in phase II-IV throughout Europe with in-house capabilities such as project management, monitoring, data management and biostatistics, medical writing and quality assurance. IMRO TRAMARKO employs about 40 people.

*"We have been collaborating with IMRO TRAMARKO for close to 10 years and feel very confident in the senior management, operational deliveries of the company and the quality of services. The acquisition is from our point of view seen as a natural development of a long and successful business relation between our companies. It is in addition to that giving us comprehensive access to the markets of the Benelux region"* says Mr. Daniel Spasic, Chief Executive Officer of the TFS Group.

After the acquisition, Mr. Anton Bonefaas, currently Managing Director of IMRO TRAMARKO, will oversee operations in the Benelux region. Mr. Anton Bonefaas has more than 12 years of experience with IMRO TRAMARKO, having spent the past two years as Managing Director.

*"We are delighted that we are going to play a role in a large international organization. The trends for CROs over the last years are either to grow or to specialize as a niche CRO; we have chosen for the first. We fill in an important area for TFS and we are convinced that we can contribute in the planned strategic growth"* says Mr. Peter Monster and Mr. Ed Dawson, the two owners of IMRO TRAMARKO Holding.



TFS TRIAL FORM SUPPORT INTERNATIONAL

## **PRESS RELEASE**

The acquisition will impact the period of May - December, adding revenues of 1700 KEUR which is an increase of 5% to the estimated budget and will contribute with 220 KEUR which is 6% of the estimated EBIT of 2008. IMRO TRAMARKO's subsidiaries IMRO TRAMARKO International B.V. and IMRO TES B.V. with focus on project delivery in phase II-IV and training, employment and staffing services respectively, will be further strengthened and developed within the TFS Group.

### **For further information please contact:**

Mr. Daniel Spasic, Chief Executive Officer  
TFS Trial Form Support International AB  
Telephone: + 46 8 440 76 00

### **Information about TFS Trial Form Support International (TFS)**

TFS is a full-service clinical CRO, providing the pharmaceutical, biotechnological, medical device, diagnostic and functional food industries with a wide range of clinical trial services. TFS services cover the whole clinical development programme from early explorative Phase I trials to registration trials in Phases II-III and post marketing surveillance trials in Phase IV. Over 420 highly competent employees dedicated to accuracy and service are working from multiple offices spread throughout 15 countries in Europe, India, Japan, and the USA.



TFS TRIAL FORM SUPPORT INTERNATIONAL